Coronary Artery Disease in China
Overview
Coronary artery disease (CAD) develops when cholesterol plaque gradually narrows the arteries that supply blood to the heart muscle, limiting oxygen delivery and ranging from stable angina to acute heart attack. It is the leading cause of death worldwide, yet with modern diagnostic tools and revascularization techniques it is also one of the most treatable chronic conditions.
China’s top cardiac centers combine enormous procedural volume with advanced imaging and hybrid operating rooms, allowing every stage of disease — from first diagnostic catheterization to complex multivessel bypass — to be planned and delivered by dedicated heart teams.
Symptoms & Signs
Chest pressure or tightness (angina) triggered by exertion or emotion, typically relieved by rest
Shortness of breath and progressively reduced exercise tolerance
Unexplained fatigue, or atypical chest, jaw, back or epigastric discomfort — especially in women and diabetic patients
Palpitations, sweating and nausea accompanying pain episodes
Heart attack: severe crushing chest pain lasting more than 15 minutes with sweating and collapse — a medical emergency
Many narrowing lesions cause no symptoms until a sudden plaque rupture, which is why screening matters for high-risk patients
Diagnosis
Resting ECG and treadmill exercise stress testing with continuous monitoring
Echocardiography assessing heart muscle function and complications such as ischemic mitral regurgitation
Coronary CT angiography (CCTA) as a non-invasive anatomic roadmap with calcium scoring
Invasive coronary angiography — the gold standard — combined with FFR pressure-wire measurement of borderline lesions
Intravascular ultrasound (IVUS) or OCT imaging defining plaque burden before stenting
Laboratory profiling: lipids, HbA1c, kidney function and high-sensitivity troponin
Treatment Options
Guideline-directed medication as the first line: statins, antiplatelet agents, beta-blockers, ACE inhibitors and rigorous risk-factor control
PCI: balloon angioplasty with drug-eluting stents for significant narrowings, via wrist (radial) access with next-day discharge in selected cases
CABG bypass surgery for complex multivessel or left-main disease, using arterial grafts for superior long-term durability
Hybrid revascularization combining minimally invasive bypass and stenting in the same setting for selected anatomy
Cardiac rehabilitation programs integrating exercise prescription, nutrition and secondary-prevention medication tuning
Chronic total occlusion (CTO) recanalization by dedicated high-volume operators for previously untreatable vessels
Advanced Technologies & Novel Drug
Intravascular imaging (IVUS/OCT) and physiology (FFR, FFR-CT) guiding precise, evidence-based stent placement
Rotational and laser atherectomy for heavily calcified arteries
Robotic-assisted PCI and minimally invasive CABG in hybrid operating rooms
Domestically manufactured novel drug-eluting stents and bioresorbable scaffolds approved in China
Novel lipid-lowering agents including PCSK9 inhibitors and siRNA therapies (incluisiran-class) available at major centers
Hospital & Specialist
- Fuwai Hospital, Chinese Academy of Medical Sciences (Fuwai Hospital, CAMS & PUMC) — Beijing
- Zhongshan Hospital, Fudan University — Shanghai
- Tianjin Medical University General Hospital — Tianjin
- The Second Hospital of Tianjin Medical University — Tianjin
- Fang Quan — Cardiology
- Ni Chao — Cardiology
- Xu Jing — Cardiology
- Li Jian Hua — Cardiac Surgery